107 related articles for article (PubMed ID: 34410104)
1. Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer.
Shahdeo D; Chandra AB; Gandhi S
Anal Chem; 2021 Aug; 93(34):11868-11877. PubMed ID: 34410104
[TBL] [Abstract][Full Text] [Related]
2. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952
[TBL] [Abstract][Full Text] [Related]
3. Polymeric biocompatible iron oxide nanoparticles labeled with peptides for imaging in ovarian cancer.
Shahdeo D; Roberts A; Kesarwani V; Horvat M; Chouhan RS; Gandhi S
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35103283
[TBL] [Abstract][Full Text] [Related]
4. Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells.
Park JY; Shin Y; Won WR; Lim C; Kim JC; Kang K; Husni P; Lee ES; Youn YS; Oh KT
Int J Nanomedicine; 2021; 16():5437-5449. PubMed ID: 34408417
[TBL] [Abstract][Full Text] [Related]
5. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
6. Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Hansen L; Larsen EK; Nielsen EH; Iversen F; Liu Z; Thomsen K; Pedersen M; Skrydstrup T; Nielsen NC; Ploug M; Kjems J
Nanoscale; 2013 Sep; 5(17):8192-201. PubMed ID: 23835641
[TBL] [Abstract][Full Text] [Related]
7. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
14. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Qin W; Zhu W; Wagner-Mann C; Sauter ER
Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
[TBL] [Abstract][Full Text] [Related]
15. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
16. Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.
Avvakumova S; Galbiati E; Pandolfi L; Mazzucchelli S; Cassani M; Gori A; Longhi R; Prosperi D
Bioconjug Chem; 2014 Aug; 25(8):1381-6. PubMed ID: 25080049
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
18. Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Roberts A; Tripathi PP; Gandhi S
Biosens Bioelectron; 2019 Sep; 141():111398. PubMed ID: 31176112
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
20. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Chung HC; Rha SY; Park JO; Yoo NC; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Kim JJ
Breast Cancer Res Treat; 1998 May; 49(1):41-50. PubMed ID: 9694610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
